Maze Therapeutics Inc(MAZE) - 2024 Q4 - Annual Results

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN FRANCISCO, CA, March 31, 2025 – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage bio ...